| abstract |
IT REFERS TO A PHARMACEUTICAL COMPOSITION CONTAINING: A) A GPR119 AGONIST; AND B) AN INHIBITOR OF DIPEPTIDYL PEPTIDASE IV (DPP-IV) SUCH AS i) MK-0431 OR 3 (R) -AMINO-1- [3- (TRIFLUOROMETIL) -5,6,7,8-TETRAHYDRO [1, 2,4] TRIAZOLO [4,3-a] PIRAZIN-7-IL] -4- (2,4,5-TRIFLUOROPHENYL) BUTAN-1-ONA, ii) LAF237 O (1 - [[3-HYDROXY-1 -ADAMANTIL) AMINO] ACETYL] -2-CYANE- (S) -PYRROLIDINE, E iii) BMS-477118 O (1S, 3S, 5S) -2- [2 (S) -AMINO-2- (3-HYDROXYADAMANTAN- 1-IL) ACETYL] -2-AZABICYCLE [3.1.0] HEXANE-3-CARBONITRILE. IT ALSO REFERS TO A METHOD OF PREPARATION OF SUCH COMPOSITION WHICH INCREASES THE CONCENTRATION OF GLP-1 BEING USEFUL IN THE TREATMENT OF TYPE 2 DIABETES, INSULIN RESISTANCE, METABOLIC ACIDOSIS, ATHEROSCLEROSIS |